showed that a decrease in baseline CD4+ CM T cells in 7 out of 10 patients with head and neck squamous cell carcinoma exhibiting PR or SD to PD-1 inhibitor nivolumab (32). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.